Analytical Data
-
Gene name
CCL26
- Application
-
Alternative Names
CCL26；SCYA26；C-C motif chemokine 26
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y258
-
Expression Region
24-94aa
-
AA Sequence
TRGSDISKTC CFQYSHKPLP WTWVRSYEFT SNSCSQRAVI FTTKRGKKVC THPRKKWVQK YISLLKTPKQ L
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL26, also known as eotaxin-3, is a member of the CC chemokine family, primarily involved in the recruitment of eosinophils and Th2 cells to sites of inflammation, particularly in allergic and asthmatic conditions. Research has highlighted its critical role in various pathophysiological processes, including asthma, atopic dermatitis, and tissue remodeling. The interest in CCL26 recombinant protein has surged due to its potential as a therapeutic target for allergic diseases, where elevated levels are often observed. Furthermore, understanding the precise molecular mechanisms by which CCL26 mediates immune responses and tissue inflammation can provide insights into novel treatment strategies. The recombinant form of CCL26 allows for in-depth studies of its biological activity, receptor interactions, and downstream signaling pathways, facilitating the exploration of its role in immune modulation. By investigating CCL26's structure-function relationships and its interactions with other immune mediators, researchers aim to develop effective interventions that can mitigate the adverse effects of excessive eosinophil recruitment and activation in allergic diseases. This ongoing research not only holds promise for enhancing current therapeutic options but also aims to elucidate the broader implications of chemokines in the regulation of immune responses and the development of targeted therapies for inflammatory conditions.
